Solid Tumor

Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA Germany (OTC: MKGAF). The payment is related to a patient enrollment achievement in the Phase 1 dose-escalation and...

Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT-005 trial in patients with solid tumors. The trial will evaluate the feasibility, safety, and efficacy of Immutep...

Immutep Limited (NASDAQ: IMMP) has announced that data from its TACTI-002 and INSIGHT-004 studies have been published in abstracts for the American Society of Clinical Oncology's 2021 Annual Meeting. Data from Phase I INSIGHT trial evaluating eftilagimod alpha...

Black Diamond Therapeutics Inc (NASDAQ: BDTX) reported initial data from the Phase 1 dose-escalation portion of the Phase 1/2 MasterKey-01 trial evaluating BDTX-189 in patients with advanced solid tumors. The data will be presented at the American Society of Clinical...

Bristol-Myers Squibb Co (NYSE: BMY) and Agenus Inc (NASDAQ: AGEN) have entered into a global exclusive license agreement, under which Bristol Myers will receive an exclusive license to Agenus' AGEN1777 and a second undisclosed target. Bristol Myers Squibb will become solely...

ImmunityBio Inc (NASDAQ: IBRX) has received FDA authorization to conduct a Phase 1 study to evaluate the m-ceNK platform combined with Anktiva (N-803) in locally advanced/metastatic solid tumors. Cryopreserved m-ceNK cells combined with Anktiva will be tested in this QUILT 3....

Nanobiotix (NASDAQ: NBTX) has announced a partnership with LianBio to develop and commercialize Nanobiotix's lead product candidate NBTXR3, in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore, and Thailand. NBTXR3 comprises...

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTCMKTS: ALPMF) The data were presented at the American Society for Cell and Gene...

Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) has a preclinical nonhuman primate GLP repeat-dose study of SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) platform. The FHAB technology targets the tumor and...

SpringWorks Therapeutics Inc (NASDAQ: SWTX) has entered into an exclusive worldwide license agreement with Katholieke Universiteit Leuven (KU Leuven) and the Flanders Institute for Biotechnology (VIB) for the in-license of small molecule inhibitors of the TEA domain (TEAD)...

The FDA has removed the clinical hold related to Neoleukin Therapeutics Inc (NASDAQ: NLTX) investigational new drug application, to begin a Phase 1 program of its cancer immunotherapeutic candidate, NL-201. Back in January this year, the FDA asked the company for more...

Galectin Therapeutics Inc (NASDAQ: GALT) has announced that a paper in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC) published data from an ongoing Phase 1 trial evaluating Galectin's belapectin in head & neck cancer, lung cancer, and...

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) has announced initial efficacy and safety data from the Phase 1 dose-escalation portion of its ongoing Phase 1/2 trial evaluating ZN-c3 in patients with advanced solid tumors who are refractory to or ineligible for standard therapy or...

Turning Point Therapeutics Inc (NASDAQ: TPTX) has reported initial data from the ongoing Phase 1/2 SWORD-1 study evaluating its RET inhibitor drug candidate, TPX-0046, in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations....